Chikungunya virus virus-like particle vaccine (VIMKUNYA) elicits cross-neutralization across CHIKV lineages and against other alphaviruses after just one dose.
VaccineJul 9, 2026 (epub)
Clinical ResearchInfectious Diseases
Christina L Gardner, Nikia N Brown, Jennifer L Brown et al.
✦ AI-curated · Sources linked
In 30 seconds
This Phase II clinical trial evaluated the CHIKV virus-like particle vaccine (VIMKUNYA) in participants to assess its ability to induce cross-neutralizing antibodies against various CHIKV lineages and other alphaviruses after a single dose. The study found that the vaccine elicited cross-neutralizing antibodies against multiple CHIKV strains and related viruses, regardless of prior alphavirus vaccination status.
Key findings
- A single dose of VIMKUNYA induced cross-neutralizing antibodies against multiple CHIKV lineages.
- The vaccine generated measurable cross-neutralizing activity against several related arthritogenic alphaviruses.
- Participants with prior alphavirus vaccination had immune responses comparable to alphavirus-naïve individuals.
Why it matters
The findings suggest that the VIMKUNYA vaccine could provide broad protection against chikungunya and related viruses, which is crucial for managing outbreaks and protecting vulnerable populations.